---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059380"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2026-05-12T20:06:21+00:00"
generated_at: "2026-05-12T21:29:10.085088+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Capricor Q1 net loss $33.9M ($0.59/share); Deramiocel BLA PDUFA Aug 22, 2026

## Summary
- Net loss of $33.9M ($0.59/share) for Q1 2026 vs net loss of $24.4M ($0.53/share) in Q1 2025.
- Cash balance of $278.6M as of March 31, 2026; expected to support operations through Q4 2027.
- Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected soon.
- Filed suit against Nippon Shinyaku/NS Pharma citing flawed pricing in distribution agreement; seeking rescission and preliminary injunction.
- New Chief Commercial Officer with direct DMD experience expected to join in coming weeks; eligible for Priority Review Voucher upon approval.

## SEC filing metadata
- accession: 0001104659-26-059380
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2026-05-12T20:06:21+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/0001104659-26-059380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/capr-20260512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059380
- JSON: https://secwatch.observer/filing/0001104659-26-059380.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059380.txt

## Key facts
- Earnings Releases
  CAPRICOR THERAPEUTICS, INC. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: today announced its financial results for the first quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/0001104659-26-059380-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.